Future is Brighter: New Potential Paradigm-Shifting Medications and Regimens for Diabetes and Obesity

Overview

Journal Curr Diabetes Rev

Publisher Bentham Science Publishers

Specialty Endocrinology

Date 2024 Jan 26

PMID 38275036

Authors

Rami A Al-Horani

Kholoud F Aliter

Hashem F Aliter

Affiliations

Soon will be listed here.

Abstract

Diabetes is a chronic illness that can become debilitating owing to its microvascular and macrovascular complications. Its prevalence is increasing and so is its cost. Diabetes, particularly type 2, appears to have a very close relationship with obesity. While lifestyle modifications, exercises, and current therapeutics have substantially improved clinical outcomes, the need for new therapeutics and regimens continue to exist. Several new medications and regimens for diabetes, obesity, and diabesity are showing promising results in advanced clinical trials. For type 1 diabetes mellitus (T1DM), they include teplizumab, ustekinumab, jakinibs, and cell therapies, whereas for type 2 diabetes mellitus (T2DM), they include once-weakly insulin, tirzepatide, high oral dose of semaglutide, orforglipron, retatrutide, CagriSema, and survodutide. Given their structural and mechanistic diversity as well as their substantial efficacy and safety profiles, these medications and regimens are paradigm shifting and promise a brighter future. They will likely enable better disease prevention and management. This review will provide details about each of the above strategies to keep the scientific community up to date about progress in the fields of diabetes and obesity.

References

Wharton S, Blevins T, Connery L, Rosenstock J, Raha S, Liu R . Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. N Engl J Med. 2023; 389(10):877-888. DOI: 10.1056/NEJMoa2302392. View

Merger S, Leslie R, Boehm B . The broad clinical phenotype of Type 1 diabetes at presentation. Diabet Med. 2012; 30(2):170-8. DOI: 10.1111/dme.12048. View

Frias J, Hsia S, Eyde S, Liu R, Ma X, Konig M . Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study. Lancet. 2023; 402(10400):472-483. DOI: 10.1016/S0140-6736(23)01302-8. View

Kruse T, Hansen J, Dahl K, Schaffer L, Sensfuss U, Poulsen C . Development of Cagrilintide, a Long-Acting Amylin Analogue. J Med Chem. 2021; 64(15):11183-11194. DOI: 10.1021/acs.jmedchem.1c00565. View

Ji L, Gao L, Jiang H, Yang J, Yu L, Wen J . Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial. EClinicalMedicine. 2022; 54:101691. PMC: 9561728. DOI: 10.1016/j.eclinm.2022.101691. View

Al-Horani R, Chedid M . Tirzepatide: A New Generation Therapeutic for Diabetes Type 2. Endocr Metab Immune Disord Drug Targets. 2022; 23(8):1046-1050. PMC: 10473544. DOI: 10.2174/1871530322666221004151212. View

Enebo L, Berthelsen K, Kankam M, Lund M, Rubino D, Satylganova A . Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet. 2021; 397(10286):1736-1748. DOI: 10.1016/S0140-6736(21)00845-X. View

. 2. Classification and Diagnosis of Diabetes: . Diabetes Care. 2017; 41(Suppl 1):S13-S27. DOI: 10.2337/dc18-S002. View

Frias J, Deenadayalan S, Erichsen L, Knop F, Lingvay I, Macura S . Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet. 2023; 402(10403):720-730. DOI: 10.1016/S0140-6736(23)01163-7. View

10.

Pettus J, Boeder S, Christiansen M, Denham D, Bailey T, Akturk H . Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial. Nat Med. 2022; 28(10):2092-2099. PMC: 9872851. DOI: 10.1038/s41591-022-02011-x. View

11.

Jastreboff A, Kaplan L, Frias J, Wu Q, Du Y, Gurbuz S . Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. 2023; 389(6):514-526. DOI: 10.1056/NEJMoa2301972. View

12.

Herold K, Bundy B, Long S, Bluestone J, DiMeglio L, Dufort M . An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. N Engl J Med. 2019; 381(7):603-613. PMC: 6776880. DOI: 10.1056/NEJMoa1902226. View

13.

Waibel M, Thomas H, Wentworth J, Couper J, MacIsaac R, Cameron F . Investigating the efficacy of baricitinib in new onset type 1 diabetes mellitus (BANDIT)-study protocol for a phase 2, randomized, placebo controlled trial. Trials. 2022; 23(1):433. PMC: 9125350. DOI: 10.1186/s13063-022-06356-z. View

14.

Carson A, Reynolds K, Fonseca V, Muntner P . Comparison of A1C and fasting glucose criteria to diagnose diabetes among U.S. adults. Diabetes Care. 2009; 33(1):95-7. PMC: 2797994. DOI: 10.2337/dc09-1227. View

15.

Garvey W, Frias J, Jastreboff A, le Roux C, Sattar N, Aizenberg D . Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023; 402(10402):613-626. DOI: 10.1016/S0140-6736(23)01200-X. View

16.

Chaimowitz N, Ebenezer S, Hanson I, Anderson M, Forbes L . STAT1 Gain of Function, Type 1 Diabetes, and Reversal with JAK Inhibition. N Engl J Med. 2020; 383(15):1494-1496. DOI: 10.1056/NEJMc2022226. View

17.

Friedman J, Dohm G, Elton C, Tapscott E, Pories W, Caro J . Restoration of insulin responsiveness in skeletal muscle of morbidly obese patients after weight loss. Effect on muscle glucose transport and glucose transporter GLUT4. J Clin Invest. 1992; 89(2):701-5. PMC: 442905. DOI: 10.1172/JCI115638. View

18.

Gregory J, Carter K, Cheung W, Holland G, Bowen-Morris J, Luzio S . Phase II multicentre, double-blind, randomised trial of ustekinumab in adolescents with new-onset type 1 diabetes (USTEK1D): trial protocol. BMJ Open. 2021; 11(10):e049595. PMC: 8524290. DOI: 10.1136/bmjopen-2021-049595. View

19.

ElSayed N, Aleppo G, Aroda V, Bannuru R, Brown F, Bruemmer D . 3. Prevention or Delay of Type 2 Diabetes and Associated Comorbidities: Standards of Care in Diabetes-2023. Diabetes Care. 2022; 46(Suppl 1):S41-S48. PMC: 9810464. DOI: 10.2337/dc23-S003. View

20.

Zimmermann T, Thomas L, Baader-Pagler T, Haebel P, Simon E, Reindl W . BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy. Mol Metab. 2022; 66:101633. PMC: 9679702. DOI: 10.1016/j.molmet.2022.101633. View